Evidence map›Paper›PMID 35769559›Full record

ArticleFrontiers in allergy2022

Impact of Food Matrices on Digestibility of Allergens and Poorly Allergenic Homologs.

J H Akkerdaas, A Cianferoni, E Islamovic, J Kough, G S Ladics, S McClain, L K Poulsen, A Silvanovich, L Pereira Mouriès, R van Ree

Open access · goldAbstract read
In one paragraph

Article in Frontiers in allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 3 countries.

J H AkkerdaasDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
A CianferoniChildren's Hospital of Philadelphia, Philadelphia, PA, United States.
E IslamovicBASF Corporation, Morrisville, NC, United States.
J KoughUS EPA, Washington, DC, United States.
G S LadicsDupont Nutrition and Biosciences, IFF, Wilmington, DE, United States.
S McClainSyngenta Crop Protection, LLC, Greensboro, NC, United States.
L K PoulsenCopenhagen University Hospital at Gentofte, Copenhagen, Denmark.
A SilvanovichBayer U.S. Crop Science, Chesterfield, MO, United States.
L Pereira MourièsHealth & Environmental Sciences Institute (HESI), Washington, DC, United States.
R van ReeDepartment of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Amsterdam University Medical Centers · NLBASF (United States) · USBayer (United States) · USChildren's Hospital of Philadelphia · USEnvironmental Protection Agency · USGentofte Hospital · DKHealth and Environmental Sciences Institute · USSyngenta (United States) · USWilmington University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Protease resistance is considered a risk factor for allergenicity of proteins, although the correlation is low. It is nonetheless a part of the weight-of-evidence approach, proposed by Codex, for assessing the allergenicity risk of novel food proteins. Susceptibility of proteins to pepsin is commonly tested with purified protein in solution. Objective: Food proteins are rarely consumed in purified form. Our aim was to evaluate the impact of experimental and endogenous food matrices on protease susceptibility of homologous protein pairs with different degrees of allergenicity. Methods: Porcine and shrimp tropomyosin (ST) were subjected to sequential exposure to amylase, pepsin, and pancreatin in their respective endogenous matrix (pork tenderloin/boiled shrimp) and in three different experimental matrices (dessert mousse [DM], soy milk [SM], and chocolate bar [CB]). Digestion was monitored by immunoblotting using tropomyosin-specific antibodies. Recombinant peach and strawberry lipid transfer protein were biotinylated, spiked into both peach and strawberry fruit pulp, and subjected to the same sequential digestion protocol. Digestion was monitored by immunoblotting using streptavidin for detection. Results: Chocolate bar, and to a lesser extent SM, had a clear protective effect against pepsin digestion of porcine tropomyosin (PT) and to a lesser extent of ST. Increased resistance was associated with increased protein content. Spiking experiments with bovine serum albumin (BSA) confirmed the protective effect of a protein-rich matrix. The two tropomyosins were both highly resistant to pepsin in their protein-rich and lean native food matrix. Pancreatin digestion remained rapid and complete, independent of the matrix. The fat-rich environment did not transfer protection against pepsin digestion. Spiking of recombinant peach and strawberry lipid transfer proteins into peach and strawberry pulp did not reveal any differential protective effect that could explain differences in allergenicity of both fruits. Conclusions: Protein-rich food matrices delay pepsin digestion by saturating the protease. This effect is most apparent for proteins that are highly pepsin susceptible in solution. The inclusion of food matrices does not help in understanding why some proteins are strong primary sensitizers while homologs are very poor allergens. Although for induction of symptoms in food allergic patients (elicitation), a protein-rich food matrix that may contribute to increased risk, our results indicate that the inclusion of food matrices in the weight-of-evidence approach for estimating the potential risks of novel proteins to become allergens (sensitization), is most likely of very limited value.

Indexed as

allergen exposureallergenicityfood matrixprotease resistancerisk assessment

Identifiers

PMID35769559
PMCPMC9234860
OpenAlexW4281860607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.